Brain Cannabinoid Signaling: Selectivity and Adaptation
大脑大麻素信号传导:选择性和适应
基本信息
- 批准号:7894922
- 负责人:
- 金额:$ 29.67万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-05-01 至 2013-07-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAgonistAntiemeticsArrestinsAttenuatedBehaviorBehavioralBindingBiochemicalBiochemical PharmacologyBody TemperatureBrainBrain regionCNR1 geneCannabinoidsCannabinolCatalepsyCell NucleusCellsChronicCorpus striatum structureDataDependenceDevelopmentDominant-Negative MutationDorsalDown-RegulationDrug abuseDynorphinsEnkephalinsFundingG-Protein-Coupled ReceptorsGTP-Binding ProteinsGene TransferGenetic ModelsGenetic TranscriptionImmunoblot AnalysisImmunoblottingImmunohistochemistryIndividualKnockout MiceLeadLigand BindingLightMarijuanaMarijuana SmokingMeasuresMediatingMemoryModelingMolecularMotorMotor ActivityMusNeuroanatomyNeuronsNucleus AccumbensPharmaceutical PreparationsPhysiologicalPropertyProteinsPsychotropic DrugsReceptor ActivationReceptor SignalingRegulationRewardsRodentRoleSignal TransductionSignaling ProteinSpinal CordStimulusTestingTetrahydrocannabinolTherapeuticTherapeutic UsesTimeTransgenic MiceTranslatingVariantWithholding TreatmentWorkaddictionarrestin 2basecannabinoid receptordesensitizationdrug of abusein vivoincreased appetiteinhibitor/antagonistmouse modelnatural hypothermianeuroadaptationoverexpressionputamenreceptorreceptor functiontranscription factor
项目摘要
69-tetrahydrocannabinol (THC), the psychoactive component of marijuana, produces a variety of effects by activating cannaibinoid CBl receptors (CB1R) in specific CNS regions. THC is widely used illicitly for its psychoactive properties, which can lead to addiction, and is the primary component of antiemetic, appetite stimulating and anti-spasticity medications. Chronic THC use produces tolerance and dependence, which might contribute to addiction and limit the therapeutic use of cannabinoids. Our previous studies revealed brain region-specific CB1R desensitization and downregulation after THC administration, and this receptor
neuroadaptation was associated with tolerance to in vivo effects. The proposed studies will elucidate the role of specific signaling proteins, J3-arrestin and 6FosB in regulation of acute and chronic CB1R signaling using mouse models with abrogated or overexpressed proteins. CBl R function will be assessed by functional neuroanatomy and biochemical pharmacology. Parallel in vivo studies will determine whether altered CB1R signaling translates into behavioral and physiological effects. Specific Aim 1 will assess CB1R function and in vivo effects in wild-type and J3-arrestin-2 null mice to test the hypothesis that J3-arrestin regulates acute and chronic CB1R signaling, THC-mediated in vivo effects (antinociception, locomotor inhibition, catalepsy, hypothermia) and tolerance. Preliminary data show that CB1R-mediated G-protein activity is increased in
na'ive J3-arrestin-2 null mouse spinal cord and CBl R desensitization following chronic THC is reduced in 13-arrestin-2 null mice. Previous studies showed that CBl R desensitization and down regulation recover by 2 weeks following chronic THC treatment and therefore lack the stability to underlie persistent changes associated with addiction. Specific Aim 2 hypothesizes that 6FosB, a stable transcription factor, is involved in chronic THC-mediated effects. The regional expression of 6FosB after THC treatment will first be examined. Then CB1R signaling and THC in vivo effects will be assessed in transgenic mice with inducible overexpression or dominant negative inactivation of 6FosB in the striatum. Preliminary studies show increased 6FosB in nucleus accumbens following chronic THC treatment, and administration of THC to 6FosB overexpressing mice revealed attenuated tolerance and CB1R desensitization in mice. These studies will elucidate cellular and molecular mechanisms that regulate CBl R signaling and neuroadaptation and translate these effects to the in vivo level. This project will determine roles of specific signaling proteins in the effects of acute and long-term CB1R activation by THC and are relevant to cannabinoid therapeutics and drug abuse.
69-大麻的精神活性成分四氢大麻酚(THC)通过激活特定CNS区域中的大麻素CB 1受体(CB 1 R)产生多种作用。THC因其精神活性而被广泛使用,这可能导致成瘾,并且是止吐,食欲刺激和抗痉挛药物的主要成分。长期使用THC会产生耐受性和依赖性,这可能会导致成瘾并限制大麻素的治疗用途。我们先前的研究揭示了THC给药后脑区域特异性CB 1 R脱敏和下调,并且该受体
神经适应与对体内效应的耐受性有关。拟议的研究将阐明特定的信号传导蛋白,J3-arrestin和6 FosB在急性和慢性CB 1 R信号传导的调节中的作用,使用废除或过表达的蛋白质的小鼠模型。将通过功能神经解剖学和生化药理学评估CBIR功能。平行的体内研究将确定改变的CB 1 R信号传导是否转化为行为和生理效应。具体目标1将在野生型和J3-抑制蛋白-2缺失小鼠中评估CB 1 R功能和体内效应,以检验J3-抑制蛋白调节急性和慢性CB 1 R信号传导、THC介导的体内效应(抗伤害感受、运动抑制、僵住症、体温过低)和耐受性的假设。初步数据显示,CB 1 R介导的G蛋白活性在
在13-抑制蛋白-2缺失小鼠中,慢性THC后的未处理的13-抑制蛋白-2缺失小鼠脊髓和CB 1 R脱敏减少。先前的研究表明,CBIR脱敏和下调在慢性THC治疗后2周恢复,因此缺乏稳定性以支持与成瘾相关的持续变化。具体目标2假设,6 FosB,一个稳定的转录因子,参与慢性THC介导的影响。首先检查THC处理后6 FosB的区域表达。然后在纹状体中具有6 FosB的诱导性过表达或显性负失活的转基因小鼠中评估CB 1 R信号传导和THC的体内作用。初步研究表明,在慢性THC治疗后,6 FosB在丘脑核中增加,并且向6 FosB过表达的小鼠施用THC显示小鼠的耐受性减弱和CB 1 R脱敏。这些研究将阐明调节CB 1 R信号传导和神经适应的细胞和分子机制,并将这些作用转化为体内水平。该项目将确定特定信号蛋白在THC急性和长期CB 1 R激活作用中的作用,并与大麻素治疗和药物滥用有关。
项目成果
期刊论文数量(9)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Sphingosine-1-phosphate receptors as emerging targets for treatment of pain.
1-磷酸鞘氨醇受体作为治疗疼痛的新兴靶点。
- DOI:10.1016/j.bcp.2012.08.010
- 发表时间:2012
- 期刊:
- 影响因子:5.8
- 作者:Welch,SandraP;Sim-Selley,LauraJ;Selley,DanaE
- 通讯作者:Selley,DanaE
Long-term administration of Delta9-tetrahydrocannabinol desensitizes CB1-, adenosine A1-, and GABAB-mediated inhibition of adenylyl cyclase in mouse cerebellum.
长期施用 Delta9-四氢大麻酚可使小鼠小脑中 CB1-、腺苷 A1- 和 GABAB 介导的腺苷酸环化酶抑制变得不敏感。
- DOI:10.1124/mol.104.000604
- 发表时间:2004
- 期刊:
- 影响因子:3.6
- 作者:Selley,DanaE;Cassidy,MichaelP;Martin,BillyR;Sim-Selley,LauraJ
- 通讯作者:Sim-Selley,LauraJ
Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids.
- DOI:10.1615/critrevneurobiol.v15.i2.10
- 发表时间:2003-01-01
- 期刊:
- 影响因子:0
- 作者:Sim-Selley, Laura J.
- 通讯作者:Sim-Selley, Laura J.
Statistical Parametric Mapping reveals ligand and region-specific activation of G-proteins by CB1 receptors and non-CB1 sites in the 3D reconstructed mouse brain.
- DOI:10.1016/j.neuroimage.2010.04.259
- 发表时间:2010-10-01
- 期刊:
- 影响因子:5.7
- 作者:Nguyen, P. T.;Selley, D. E.;Sim-Selley, L. J.
- 通讯作者:Sim-Selley, L. J.
Brain regional differences in CB1 receptor adaptation and regulation of transcription.
- DOI:10.1016/j.lfs.2012.08.023
- 发表时间:2013-03-19
- 期刊:
- 影响因子:6.1
- 作者:Lazenka, M. F.;Selley, D. E.;Sim-Selley, L. J.
- 通讯作者:Sim-Selley, L. J.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Laura J Sim-Selley其他文献
FAAH−/− Mice Display Differential Tolerance, Dependence, and Cannabinoid Receptor Adaptation After Δ9-Tetrahydrocannabinol and Anandamide Administration
FAAH−/− 小鼠在给予 Δ9-四氢大麻酚和花生四烯酸乙醇胺后表现出差异耐受性、依赖性和大麻素受体适应性
- DOI:
10.1038/npp.2010.44 - 发表时间:
2010-03-31 - 期刊:
- 影响因子:7.100
- 作者:
Katherine W Falenski;Andrew J Thorpe;Joel E Schlosburg;Benjamin F Cravatt;Rehab A Abdullah;Tricia H Smith;Dana E Selley;Aron H Lichtman;Laura J Sim-Selley - 通讯作者:
Laura J Sim-Selley
Laura J Sim-Selley的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Laura J Sim-Selley', 18)}}的其他基金
Brain Cannabinoid Signaling: Selectivity and Adaptation
大脑大麻素信号传导:选择性和适应
- 批准号:
6727639 - 财政年份:2002
- 资助金额:
$ 29.67万 - 项目类别:
Brain Cannabinoid Signaling: Selectivity and Adaptation
大脑大麻素信号传导:选择性和适应
- 批准号:
6624182 - 财政年份:2002
- 资助金额:
$ 29.67万 - 项目类别:
Brain Cannabinoid Signaling: Selectivity and Adaptation
大脑大麻素信号传导:选择性和适应
- 批准号:
7060755 - 财政年份:2002
- 资助金额:
$ 29.67万 - 项目类别:
Brain Cannabinoid Signaling: Selectivity and Adaptation
大脑大麻素信号传导:选择性和适应
- 批准号:
6888151 - 财政年份:2002
- 资助金额:
$ 29.67万 - 项目类别:
Brain Cannabinoid Signaling: Selectivity and Adaptation
大脑大麻素信号传导:选择性和适应
- 批准号:
6472884 - 财政年份:2002
- 资助金额:
$ 29.67万 - 项目类别:
Brain Cannabinoid Signaling: Selectivity and Adaptation
大脑大麻素信号传导:选择性和适应
- 批准号:
7741166 - 财政年份:2002
- 资助金额:
$ 29.67万 - 项目类别:
ALCOHOL EFFECTS ON RECEPTOR G PROTEIN COUPLING
酒精对受体 G 蛋白偶联的影响
- 批准号:
2894293 - 财政年份:1998
- 资助金额:
$ 29.67万 - 项目类别:
ALCOHOL EFFECTS ON RECEPTOR G PROTEIN COUPLING
酒精对受体 G 蛋白偶联的影响
- 批准号:
2875359 - 财政年份:1998
- 资助金额:
$ 29.67万 - 项目类别:
LOCALIZATION OF RECEPTOR ACITIVITY FOR DRUGS OF ABUSE
滥用药物受体活性的定位
- 批准号:
2012774 - 财政年份:1996
- 资助金额:
$ 29.67万 - 项目类别:
LOCALIZATION OF RECEPTOR ACITIVITY FOR DRUGS OF ABUSE
滥用药物受体活性的定位
- 批准号:
2897612 - 财政年份:1996
- 资助金额:
$ 29.67万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 29.67万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 29.67万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 29.67万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 29.67万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 29.67万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 29.67万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 29.67万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 29.67万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 29.67万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 29.67万 - 项目类别:
Grant-in-Aid for Scientific Research (C)